结肠癌患者凝血与纤溶分子标志物的检测及其临床意义.doc

结肠癌患者凝血与纤溶分子标志物的检测及其临床意义 目录 TOC \o "1-9" \h \z \u 目录 1 正文 1 文1：结肠癌患者凝血与纤溶分子标志物的检测及其临床意义 1 1　资料与方法 3 2　结果 4 3　讨论 4 文2：手指再造术患者凝血与纤溶系统的变化及其临床意义 6 1 资料与方法 7 2　结果 8 3　讨论 8 参考文摘引言： 9 原创性声明（模板） 11 文章致谢（模板） 11 正文 结肠癌患者凝血与纤溶分子标志物的检测及其临床意义 文1：结肠癌患者凝血与纤溶分子标志物的检测及其临床意义 【ABSTRACT】 Objective: To investigate the relatiohip between the changes of blood coagulation and fibrinolytic paramete with the pathological types, differentiation degree and metastasis in patients with colon cancer. Methods: By enzyme-linked immunosorben Assay(ELISA),4 plasma molecular marke of the coagulation and fibrinolysis systems were measured in 54 healthy voluntee and 125 cases of colon cance, which included 58 Dukes A+B, 67 Dukes C+D and 40 undifferentiated and poorly differentiated, 85 well-differentiated and moderately differentiated patients. Their blood samples were taken from their peripheral molecular marke of coagulation and fibrinolytic system were as followings：tissue factor(TF), thrombin-antithrombin III complexes(TAT)， tissue-type plasminogen activator(t-PA)， plasminogen activator inhibitor-1(PAI-1).Results: The levels of TF、TAT、t-PA、PAI-1 in 125 colon cancer patients were significantly higher than that in control group(P<). The levels of TF、TAT、t-PA、PAI-1 increased progressively with the exacerbation and differentiation of colon cancer, and there was a significant difference between the two groups (P<). Conclusion: The patients with colon cancer, especially those in the advanced stage usually, accompany with the dysfunction of blood coagulation, monitoring their alteratio in TF、TAT、t-PA、PAI-1 levels could be a valid measure to prevent coagulation disorder and to direct the clinical use of anticoagulation drugs. 【KEY WORDS】 Colon neoplasms·Blood coagulation facto·Fibrinolysis 恶性肿瘤会导致凝血、抗凝和纤溶系统的失衡， 使机体处于高凝状态[1]， 从而影响肿瘤的生长与转移[2]。1878年Biuroth发现血栓中存在恶性肿瘤细胞，从而认为血栓与恶性肿瘤转移有关。恶性肿瘤患者血栓发生率约为10%～30% ，其中以腺癌的发生率最高。本研究对125例结肠癌初诊患者检测凝血和纤溶的分子标志物，观察恶性肿瘤患者凝血、纤溶系统的变化，旨在分析和探